GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
“Together these patents provide important intellectual property protection for GlycoMimetics' lead program”
"Together these patents provide important intellectual property protection for GlycoMimetics' lead program," said Rachel King, Chief Executive Officer. "The issuance of these patents also confirms that mimics of naturally occurring carbohydrates, which are the basis of the Company's technology, represent new and inventive chemical structures."
GlycoMimetics recently announced that GMI-1070 has entered Phase 2 clinical testing with the enrollment of the first patient in the Company's clinical trial testing GMI-1070 in treatment of sickle cell crisis. The Company also announced that the U.S. Food and Drug Administration has granted Fast Track and Orphan Drug Status to the program.
Seed IP Law Group in Seattle, Washington serves as GlycoMimetics' patent counsel.
Duke-NUS team develops test to monitor engineered T cells in cancer treatment